The team

Department of Medicinal Chemistry

The department of Medicinal Chemistry is involved in Drug Discovery, i.e. the design, synthesis, purification, structural elucidation and study of structure-activity relationships of original heterocyclic molecules as antifungal, antiparasitic and antibacterial drug candidates. The physicochemical and ADME-Tox properties of compounds of biological interest are also discussed in all the projects.

Teacher-researchers

Pascal MARCHAND

Professor - Head of Department

Marc-Antoine BAZIN

Associate Professor

Muriel DUFLOS

Professor

Cédric LOGÉ

Associate Professor

Jean-Michel ROBERT

Professor

Christelle AMBEU

Visiting Scientist

Thomas YVORRA

Attaché Temporaire d'Enseignement et de Recherche

Technical staff

Jérôme THIEFAINE

Technician

Justine BONNET

Technician

Tatiana BERNOUSSI

Technician

PhD students

Post-doctoral researcher

Other departments


Department of Bacterial Resistances

The Department of Bacterial Resistances studies how interactions between the host, its microbiota and drugs (particularly anti-infective drugs, but not exclusively) influence bacterial resistance to antibiotics. We are working in particular on digestive colonisation by multi-resistant Enterobacteriaceae, and are testing the possibility of treating this colonisation with live bacteria ('probiotics') or polysaccharides ('prebiotics'). We are also working on improving the use of antibiotics, with the aim of ensuring effective treatment of bacterial infections (particularly pneumonia and community-acquired urinary tract infections) while minimising the risk of emergence, persistence and spread of multi-resistant bacteria.

Department of Medical Mycology and Parasitology

The Department of Medical Mycology and Parasitology is supported by university and hospital-university staff, enabling it to focus on health-related issues. Research strategies benefit from expertise in cell culture, signalling, molecular biology, immunology applied to microbiology, recombinant protein production (P2R platform) and in vivo models. Its activities focus mainly on resistance issues and the discovery of new therapeutic targets.